Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma

- Therapeutic options for advanced MPM are limited.
- Vinca alkaloids are active in treatment-naïve and pre-treated MPM patients.
- The role of vinca alkaloids in first-line treatment of MPM is marginal.
- Vinorelbine is a reasonable option in the second and third-line setting.
- Predictive biomarkers of vinorelbine efficacy in MPM are under evaluation.

Therapeutic options for malignant pleural mesothelioma (MPM) are limited. Most patients are treated with chemotherapy during the course of their disease. The combination of pemetrexed with a platinum compound is the standard of care in the first-line setting, while no established treatment exists in the second and beyond-line setting. Vinca alkaloids are chemotherapeutic agents that have demonstrated clinical efficacy both as single agents and in combination in a broad spectrum of cancers, including MPM. Vinorelbine has shown activity in MPM patients as neoadiuvant therapy, first-line treatment, and in the second and third-line setting. Vinflunine is a derivative of vinorelbine that has been studied in MPM as first-line agent.While the role of vinca alkaloids in the first-line treatment of MPM seems marginal, treatment with vinorelbine remains a reasonable option for pemetrexed-pretreated patients in clinical practice, based on an acceptable rate of stable disease, confirmed by several trials. Ongoing studies on predictive biomarkers for vinorelbine will hopefully be able to individualize treatment, increasing response rates and survival outcomes.